Vera Therapeutics, Inc.
VERA
Rank in Stocks
#5594
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Share Price
$30.61
Last synced: 2026-11-09
Market Cap
$2.21B
Change (1 day)
2.77%
Change (1 year)
7.90%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Vera Therapeutics, Inc. (VERA)
Category
Healthcare
EPS for Vera Therapeutics, Inc. (VERA)
EPS as of September 2026 TTM: $-5.90
According to Vera Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-5.90. At the end of 2025 the company had an EPS of $-4.66, a decrease compared to its 2024 EPS of $-2.75.
EPS history for Vera Therapeutics, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.90 | 26.61% |
| 2025 | $-4.66 | 69.45% |
| 2024 | $-2.75 | 22.22% |
| 2023 | $-2.25 | -32.84% |
| 2022 | $-3.35 | 37.86% |
| 2021 | $-2.43 | -83.13% |
| 2020 | $-14.40 | 316.18% |
| 2019 | $-3.46 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -365.42% |
US
|
|
| $-7.07 | 19.83% |
US
|
|
| $-5.29 | -10.34% |
AU
|
|
| $12.88 | -318.31% |
BE
|
|
| $21.56 | -465.42% |
NL
|
Questions about Vera Therapeutics, Inc.'s earnings per share (EPS)
What is Vera Therapeutics, Inc.'s earnings per share (EPS)?
Vera Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-5.90, as of Sep 2026.
What was Vera Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Vera Therapeutics, Inc.'s earnings per share (EPS) was $-4.66, compared with $-2.75 in 2024.
How has Vera Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vera Therapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($-2.25) and lowest in 2020 ($-14.40).
How does Vera Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Vera Therapeutics, Inc.'s earnings per share (EPS) ($-5.90) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.